diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/2072-0351-5765diaendo-5765Research ArticleСтатьиArticlesФармакоэкономические аспекты лечения сахарного диабета 2 типаFarmakoekonomicheskie aspekty lecheniya sakharnogo diabeta 2 tipaНедосуговаЛюдмила ВикторовнаNedosugovaLyudmila Viktorovna-ММА им. И.М. Сеченова, Москва200815062008112№2 (2008)7679Copyright © Недосугова Л.В., 20082008Недосугова Л.В.Nedosugova L.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/5765

Подходя к решению проблемы выбора сахароснижающих препаратов и их комбинаций с целью эффективного и экономически выгодного достижения адекватного гликемического контроля, следует опираться на применение наиболее эффективных и одновременно дешевых средств. Наиболее предпочтительными в этом отношении являются препараты компании Берлин-Хеми/Менарини, поставляющей на наш рынок как средство первого выбора для начала пероральной сахароснижающей терапии ? метформин (Сиофор?), так и наиболее эффективный ПСМ второй генерации ? глибенкламид (Манинил? в микронизированной форме), назначение которого показано для интенсификации сахароснижающей терапии в комбинации с Сиофором?. Наименьшего уровня затрат для достижения лучшего гликемического контроля по сравнению с раздельной комбинацией ПСМ и метформина можно добиться при использовании препарата глибомет на меньших дозах метформина и глибенкламида, входящих в состав Глибомета?.

фармакоэкономикасахарный диабетлечениеReferencesWorld Health Organisation: «The World Health Report 1998. Life in 21st Century - a Vision for ALL» Geneva: World Health Organisation, 1998.World Health Organisation: «The World Health Report 1998. Life in 21st Century - a Vision for ALL» Geneva: World Health Organisation, 1998.American Diabetes Association: «Economic costs of diabetes in the U.S. In 2007». Diabetes Care. 2008 Mar;31(3):596-615American Diabetes Association: «Economic costs of diabetes in the U.S. In 2007». Diabetes Care. 2008 Mar;31(3):596-615Hsueh WA, Law RE: «Cardiovascular risk continuum: Implications of insulin resistance and diabetes». Am J Med 1998; 105:4S-14SHsueh WA, Law RE: «Cardiovascular risk continuum: Implications of insulin resistance and diabetes». Am J Med 1998; 105:4S-14SO'Brien R.C., Luo M. The effects of gliclazide and other sulfonylureas on low-density lipoprotein oxidation in vitro. Methabolism. 1997; 46 (Suppl 1): 22-25.O'Brien R.C., Luo M. The effects of gliclazide and other sulfonylureas on low-density lipoprotein oxidation in vitro. Methabolism. 1997; 46 (Suppl 1): 22-25.Доборджгинидзе Л.М., Грацианский Н.А. Роль статинов в коррекции диабетической дислипидемии. // Сах. диабет.-2001.-№2.-с.41-47Доборджгинидзе Л.М., Грацианский Н.А. Роль статинов в коррекции диабетической дислипидемии. // Сах. диабет.-2001.-№2.-с.41-47Coutinho M, Gerstein HC,Wang Y, Yusuf S: The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999; 22: 233-240Coutinho M, Gerstein HC,Wang Y, Yusuf S: The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999; 22: 233-240Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:854-65. [PMID: 9742977]Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:854-65. [PMID: 9742977]Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352:837-53. [PMID: 9742976]Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352:837-53. [PMID: 9742976]Gaster B, Hirsch IB. The effects of improved glycemic control on complications in type 2 diabetes. Arch Intern Med. 1998;158:134-40. [PMID: 9448551]Gaster B, Hirsch IB. The effects of improved glycemic control on complications in type 2 diabetes. Arch Intern Med. 1998;158:134-40. [PMID: 9448551]Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular Complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-17.Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular Complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-17.Vijan S, Hofer TP, Hayward RA. Estimated benefits of glycemic control in microvascular complications in type 2 diabetes. Ann Intern Med. 1997;127:788-95.Vijan S, Hofer TP, Hayward RA. Estimated benefits of glycemic control in microvascular complications in type 2 diabetes. Ann Intern Med. 1997;127:788-95.Pitale SU, Abraira C, Emanuele NV, McCarren M, Henderson WG, PacoldI, et al. // Two years of intensive glycemic control and left ventricular function in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VACSDM). Diabetes Care. 2000;23:1316-20. [PMID: 10977025]Pitale SU, Abraira C, Emanuele NV, McCarren M, Henderson WG, PacoldI, et al. // Two years of intensive glycemic control and left ventricular function in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VACSDM). Diabetes Care. 2000;23:1316-20. [PMID: 10977025]Stettler C, Allemann S, Ju.ni P, Cull CA, Holman RR, Egger M, et al.//Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus:meta-analysis of randomized trials. Am Heart J. 2006;152:27-38.Stettler C, Allemann S, Ju.ni P, Cull CA, Holman RR, Egger M, et al.//Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus:meta-analysis of randomized trials. Am Heart J. 2006;152:27-38.Gilmer TP, O'Connor PJ, Manning WG, Rush WA.//The cost to health plans of poor glycemic control. Diabetes Care. 1997;20:1847-1853.Gilmer TP, O'Connor PJ, Manning WG, Rush WA.//The cost to health plans of poor glycemic control. Diabetes Care. 1997;20:1847-1853.Testa MA, Simonson DC. //Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled, double-blind trial. JAMA. 1998;280:1490-1496Testa MA, Simonson DC. //Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled, double-blind trial. JAMA. 1998;280:1490-1496American Diabetes Association : Standards of medical care in diabetes- 2006. Diabetes Care 2006; 29 (Suppl. 1):S4-42.American Diabetes Association : Standards of medical care in diabetes- 2006. Diabetes Care 2006; 29 (Suppl. 1):S4-42.D. M. Nathan, J.B. Buse, M. B. Davidson, R. J. Heine, R. R. Holman,D. M. Nathan, J.B. Buse, M. B. Davidson, R. J. Heine, R. R. Holman,R. Sherwin, B. Zinman// Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy/ Diabetes Care 2006, 29 :1963-1971 18. Reaven GM 2000 Insulin resistance and its consequences: type 2 diabetes mellitus and coronary heart disease. In: LeRoith D, Taylor SI, Olefsky JM, eds. Diabetes mellitus: a fundamental and clinical text. Philadelphia: Lippincott Williams & Wilkins; 604-615.R. Sherwin, B. Zinman// Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy/ Diabetes Care 2006, 29 :1963-1971 18. Reaven GM 2000 Insulin resistance and its consequences: type 2 diabetes mellitus and coronary heart disease. In: LeRoith D, Taylor SI, Olefsky JM, eds. Diabetes mellitus: a fundamental and clinical text. Philadelphia: Lippincott Williams & Wilkins; 604-615.Kahn CR 1994 Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes 43:1066-1084.Kahn CR 1994 Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes 43:1066-1084.Hollenbeck C, Reaven GM 1987 Variations in insulin-stimulated glucose uptake in healthy individuals with normal glucose tolerance. J Clin Endocrinol Metab 64:1169-1173.Hollenbeck C, Reaven GM 1987 Variations in insulin-stimulated glucose uptake in healthy individuals with normal glucose tolerance. J Clin Endocrinol Metab 64:1169-1173.Reaven GM, Brand RJ, Chen ID, Mathur AK, Goldfine ID 1993 Insulin resistance and insulin secretion are determinants of oral glucose tolerance in normal individuals. Diabetes 42:1324-1332Reaven GM, Brand RJ, Chen ID, Mathur AK, Goldfine ID 1993 Insulin resistance and insulin secretion are determinants of oral glucose tolerance in normal individuals. Diabetes 42:1324-1332Reaven GM, Hollenbeck C, Jeng CY, Wu MS, Chen YD 1988 Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes 37:1020-1024Reaven GM, Hollenbeck C, Jeng CY, Wu MS, Chen YD 1988 Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes 37:1020-1024DeFronzo RA 1997 Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev 5:177-269.DeFronzo RA 1997 Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev 5:177-269.Froguel P, Velho G 2001 Genetic determinants of type 2 diabetes. Recent Prog Horm Res 56:91-105.Froguel P, Velho G 2001 Genetic determinants of type 2 diabetes. Recent Prog Horm Res 56:91-105.Kahn CR, Vicent D, Doria A 1996: Genetics of non-insulin-dependent (type-II) diabetes mellitus. Annu. Rev. Med. 47: 509-531.Kahn CR, Vicent D, Doria A 1996: Genetics of non-insulin-dependent (type-II) diabetes mellitus. Annu. Rev. Med. 47: 509-531.Almind K, Doria A, Kahn CR 2001 Putting the genes for type II diabetes on the map. Nat Med 7:277-279.Almind K, Doria A, Kahn CR 2001 Putting the genes for type II diabetes on the map. Nat Med 7:277-279.Taylor SI, Accili D 2000 Mutations in the genes encoding the insulin receptor and insulin receptor substrate-1. In: LeRoith D, Taylor SI, Olefsky JM, eds. Diabetes mellitus: a fundamental and clinical text. Philadelphia: Lippincott Williams & Wilkins; 681-691.Taylor SI, Accili D 2000 Mutations in the genes encoding the insulin receptor and insulin receptor substrate-1. In: LeRoith D, Taylor SI, Olefsky JM, eds. Diabetes mellitus: a fundamental and clinical text. Philadelphia: Lippincott Williams & Wilkins; 681-691.Kahn S. E., et al. for the ADOPT Study Group// Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy, N Engl J Med 2006;355:2427-43.Kahn S. E., et al. for the ADOPT Study Group// Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy, N Engl J Med 2006;355:2427-43.Демидова И.Ю. Применение пероральных сахароснижающих средств в лечении инсулиннезависимого сахарного диабета. Рус. мед. журн.1998; 6 (12): 774-8.Демидова И.Ю. Применение пероральных сахароснижающих средств в лечении инсулиннезависимого сахарного диабета. Рус. мед. журн.1998; 6 (12): 774-8.Тюрина И. В., Воробьев П. А., Авксентьева М. В. Клинико- экономический анализ применения препарата глибомет по сравнению с альтернативными схемами лечения сахарного диабета 2 типа, Проблемы стандартизации в здравоохранении. 2003 г. № 8, с. 1-4Тюрина И. В., Воробьев П. А., Авксентьева М. В. Клинико- экономический анализ применения препарата глибомет по сравнению с альтернативными схемами лечения сахарного диабета 2 типа, Проблемы стандартизации в здравоохранении. 2003 г. № 8, с. 1-4Sh. Bolen et al. Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus. Ann Intern Med. 2007;147:386-399.Sh. Bolen et al. Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus. Ann Intern Med. 2007;147:386-399.

The authors declare that there are no conflicts of interest present.